Jonathan Hopper
Vice President & Founder- Platforms OMass Therapeutics
Jonathan Hopper is Vice President, Platforms and founder of OMass Therapeutics, where he leads the development of native mass spectrometry–based technologies to interrogate protein interactions in physiologically relevant contexts. With a PhD in native MS and postdoctoral work at the University of Oxford, Jonathan has pioneered methods for studying challenging membrane protein assemblies and drug targets in near-native environments. As OMass’s first CEO, he guided the company through seed and Series A funding to build its in-house discovery engine. At the Summit, Jonathan will discuss bridging biophysics and physiology through native-context interaction mapping.
Seminars
Wednesday 29th April 2026
Native Mass Spectrometry: A New High-Throughput Platform for the Identification of Functional Hits
9:30 am
- Native mass spectrometry (MS) has been developed into a robust, high-throughput screening platform which provides a unique dataset for hit identification and prioritisation
- In combination with complimentary MS approaches, rapid identification of functional compounds can be performed
- Medicinal chemistry campaigns can be initiated from a more informed start-point, accelerating future compound design and optimisation
